Dimerix Ltd (ASX: DXB)
Dimerix is a clinical stage drug discovery and development company, based in Melbourne and Perth. Dimerix’s lead clinical program is a Phase II study in Chronic Kidney Disease, DMX-200.
Dimerix has achieved Orphan Designation from the US FDA for the constituent parts of DMX-200, for the treatment of Focal Segmental Glomerularsclerosis (FSGS). FSGS is one cause of chronic kidney disease. Orphan designation will allow Dimerix to access assistance provided by the US Orphan Product Development Office with the development of a treatment for FSGS.
The choice you make above will help our platform display content that is best suited to you
Welcome to the new Wholesale Investor platform. Please use your existing log in details to access the site. Alternatively feel free to use the "Login with LinkedIn" or "Sign in with Google" buttons.
Enter your email to reset your password.